Organovo Holdings (ONVO) shares are up sharply after the company announced positive preclinical results generated with its 3D bioprinted human liver tissues. The data, published in the journal PLOS One, showed Organovo's product was able to detect significant dose-dependent toxicity of trovafloxacin at clinically relevant doses compared to levofloxacin, a structurally similar but non-toxic compound.